TNGX 8-K 2026-11-09

Tango Therapeutics, Inc. (TNGX) 8-K dated 2026-11-09 — accession 0001193125-26-452635.

Tango Therapeutics, Inc. (TNGX) is a biotechnology company listed on NASDAQ.

TNGX: Tango Therapeutics Reports Third Quarter 2026 Financial Results

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported TNGX revenue for 2025-12-31 was $62.4M. Net income was -$101.6M. Revenue was up 48.3% from 2024-12-31 to 2025-12-31. TNGX currently screens at market cap $5.36B.

Not investment advice. The TNGX SEC hub lists recent forms. The stock page is the research view.